Search alternatives:
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
19441
-
19442
-
19443
-
19444
-
19445
-
19446
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a...
Published 2021“…At 6 months, patients experienced similar reduction in HbA1c level (-0.6 ± 0.8, -0.6 ± 0.8, -0.7 ± 0.9%, mean ± SD, respectively, noninferiority P < 0.001 vs BBI) and the proportion of patients with HbA1c ≤7.5% was also similar (34%, 28% and 27%, respectively, P = 0.489). …”
-
19447
-
19448
-
19449
-
19450
-
19451
-
19452
Effect of Cytosolic pH on Inward Currents Reveals Structural Characteristics of the Proton Transport Cycle in the Influenza A Protein M2 in Cell-Free Membrane Patches of <i>Xenopus...
Published 2014“…<div><p>Transport activity through the mutant D44A of the M2 proton channel from influenza virus A was measured in excised inside-out macro-patches of <i>Xenopus laevis</i> oocytes at cytosolic pH values of 5.5, 7.5 and 8.2. …”
-
19453
-
19454
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Published 2015“…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
-
19455
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Published 2015“…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
-
19456
-
19457
-
19458
Mean ± SEM FPKM values measured for differentially expressed genes.
Published 2015“…The mean FPKM values, P-values, sequence length, and exon density for each of these genes can be found in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0131669#pone.0131669.s005" target="_blank">S1</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0131669#pone.0131669.s007" target="_blank">S3</a> Tables.…”
-
19459
Effects of the adenosine A<sub>2A</sub> antagonist MSX-3 on PROG/chow performance.
Published 2013“…<p>On measures of lever pressing, mean (±SEM) total lever presses (A) and maximum ratio achieved (B) were both significantly increased at doses of 1.0 and 2.0 mg/kg while active lever time (measured in seconds, C) was only increased at a dose of 2.0 mg/kg. …”
-
19460